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Emerging evidence indicates that early-life exposure to environmental factors may increase
the risk for schizophrenia via inflammatory mechanisms. Inflammation can alter the
metabolism of tryptophan through the oxidative kynurenine pathway to compounds
with neurotoxic and neuroprotective activity and compromise serotonin (5-HT)
synthesis. Here we investigate the role of serotonergic and kynurenine pathways in the
maternal immune activation (MIA) animal model of schizophrenia. The potential reversion
exerted by long-term antipsychotic treatment was also evaluated. MIA was induced by
prenatal administration of polyinosinic:polycytidylic acid (poly (I:C)) in mice. Expression of
different proteins and the content of different metabolites involved in the function of
serotonergic and kynurenine pathways was assessed by RT-PCR, immunoblot and ELISA
analyses in frontal cortex of the offspring after puberty. MIA decreased tissue 5-HT content
and promoted changes in the expression of serotonin transporter, 5-HT2A and 5-HT2C
receptors. Expression of indoleamine 2,3-dioxygenase 2 (IDO2) and kynurenine 3-
monooxygenase (KMO) was increased by poly (I:C) whereas kynurenine
aminotransferase II and its metabolite kynurenic acid were not altered. Long-term
paliperidone was able to counteract MIA-induced changes in 5-HT and KMO, and to
increase tryptophan availability and tryptophan hydroxylase-2 expression in poly (I:C) mice
but not in controls. MIA-induced increase of the cytotoxic risk ratio of kynurenine
metabolites (quinolinic/kynurenic acid) was also reversed by paliperidone. MIA induces
specific long-term brain effects on serotonergic activity. Such effects seem to be related
with alternative activation of the kynurenine metabolic pathway towards a cytotoxic status.
Atypical antipsychotic paliperodine partially remediates abnormalities observed after MIA.
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INTRODUCTION
Evidence accumulated over the past decades supports the
neurodevelopmental origin of schizophrenia. Specific
alterations in brain development induced by endogenous or
exogenous factors that might be pivotal for the emergence of
the disease have begun to be identified (Marenco and
Weinberger, 2000; Lewis and Levitt, 2002; Rapoport et al.,
2012; Schmidt and Mirnics, 2015). Schizophrenia symptoms
are divided into three core clusters; positive (delusion,
hallucinations, disturbances of thoughts and paranoia),
negative (apathy, speech poverty, affect flattering, social
withdrawal and anhedonia), and cognitive symptoms
(attention and memory deficits and difficulties in planning
and organizing life). Although onset is typically in late
adolescence or early adulthood, certain clinical features of
schizophrenia can be seen in an earlier prodromal phase
(Lewis and Levitt, 2002). Signs of the different dysfunctions
depend on affected neural substrates, as the frontal cortex
(FC), and appear to emerge during the protracted maturation
of the neural circuitries throughout childhood and adolescence
(Hoftman et al., 2017).
Epidemiological studies have identified several environmental
disturbances during critical developmental periods that confer
increased risk of brain disorders (Tsuang, 2000; Sullivan et al.,
2003; van Os et al., 2010). The fact that the increased risk of
schizophrenia in offspring might be induced by a variety of
bacteria-, virus-, and parasite-induced maternal infections
during pregnancy suggests that immune-activating agents per
se are not the critical risk factor and point to the importance of the
maternal and fetal immune response in the future emergence of
the disease (Brown, 2006; Patterson, 2007; Boksa, 2008;
Khandaker et al., 2015). In that sense, numerous investigations
have reported alterations in inflammatory/immune signalling
and its regulatory mechanisms in the pathophysiology of
schizophrenia when evaluated in peripheral blood cells and in
postmortem brain studies (Khandaker et al., 2015; Leza et al.,
2015). An imbalance between pro- and anti-inflammatory
signalling has been observed in subjects with a first episode of
psychosis (García-Bueno et al., 2014a; García-Bueno et al., 2014b)
and in schizophrenia (Martínez-Gras et al., 2011). In the same
line of evidence, different meta-analyses indicate increased levels
of inflammatory cytokines in schizophrenia and psychosis (Miller
et al., 2011; Upthegrove et al., 2014; Goldsmith et al., 2016;
Fraguas et al., 2019). However, how these inflammatory and
neuroinmmune alterations are able to alter the different
neurotransmission systems implicated in schizophrenia
remains unclear.
One of the neurotransmission systems broadly involved in
schizophrenia is the serotonergic system. It has long been
recognized that psychedelic drugs, such as lysergic acid
diethylamide (LSD), psilocybin and mescaline, recruit specific
serotonin 5-HT2A receptor (5-HT2AR)-mediated signaling
pathways to exert their psychotic-like effects (González-Maeso
et al., 2007; Geyer and Vollenweider, 2008). Indeed, they are
agonists/partial agonists at the 5-HT2ARs inducing symptoms in
healthy volunteers that resemble and share similarities with the
core symptoms of schizophrenia (Gouzoulis-Mayfrank et al.,
2005; Carhart-Harris et al., 2012). In addition, there is a good
correlation between 5-HT2AR binding affinities and
hallucinogenic potencies of psychoactive drugs such as LSD
and N,N-dimethyltryptamine in humans (Glennon et al.,
1984). These facts, together with the higher affinity of atypical
antipsychotic agents such as risperidone/paliperidone, clozapine
and olanzapine, among others, for 5-HT2ARs as compared to
dopamine D2 receptors, led to the serotonin hypothesis of
schizophrenia with 5-HT2ARs being recognized as key players
(Geyer and Vollenweider, 2008; Gonzalez-Maeso and Sealfon,
2009). Nevertheless, studies carried out on postmortem human
brain of subjects with schizophrenia show some inconsistencies in
the variation of serotonin (5-HT) concentrations and 5-HT2AR
densities, so it is not clear enough so far, whether an increase or a
decrease in those levels occurs in the disease (Lovett Doust et al.,
1975; Crow et al., 1979; Bleich et al., 1988; Iqbal et al., 1991;
Ohuoha et al., 1993; Muguruza et al., 2013).
Therefore, to understand the mechanisms underlying
schizophrenia, it is essential to focus on the long-term
disturbances of postnatal brain maturation and to consider
how the initial insults in early development affect this process.
Animal models provide fundamental knowledge about the
neurobiological mechanisms of human brain disorders. Based
on construct premises described above, maternal immune
activation (MIA) during pregnancy has become one of the
most validated animal models to study schizophrenia-like
symptoms. In these models, pregnant animals are exposed to
immunological stimulation at a specific gestational stage. An
extended in-utero immune activation is commonly modeled by
injecting the viral-mimetic compound polyinosinic:polycytidylic
acid (poly (I:C)) in pregnant dams. This viral-like administration
results in activation of Toll-like receptor 3 (TLR3), a member of
TLR family of pattern recognition receptors of the innate immune
system, stimulating maternal production and release of many
pro-inflammatory cytokines (Cunningham et al., 2007; Estes and
McAllister, 2016). As consequence, the integrity of the placental
barrier is altered, allowing the entrance of maternal-derived
cytokines that would modify the physiological embryonic
development and exert long-term detrimental effects in the
offspring (Meyer, 2014; Estes and McAllister, 2016). Different
behavioral and morphofunctional brain abnormalities in
offspring of poly (I:C)-treated dams have been observed after
puberty (Zuckerman et al., 2003; Ozawa et al., 2006; Meyer and
Feldon, 2012; Meyer, 2014; Luchicchi et al., 2016). In
concordance with findings in brain of subjects with
schizophrenia, previous works confirmed that this MIA model
promotes the accumulation of pro-inflammatory mediators such
as different cytokines, as well as intracellular inflammatory and
Frontiers in Pharmacology | www.frontiersin.org May 2021 | Volume 12 | Article 6826022
MacDowell et al. Paliperidone Reversion of MIA-Induced Impairment
oxido/nitrosative mediators such as the transcription factor NFkB
or the inducible nitric oxide synthase (iNOS) (Song et al., 2011;
Volk et al., 2015; MacDowell et al., 2017; Goh et al., 2020). All
these abnormalities suggest that MIA induced by poly (I:C)
promotes in offspring a face-valid schizophrenia-like model.
Regarding the 5-HT system, an altered serotonergic axonal
circuit formation after MIA has been reported (Goeden et al.,
2016).
The serotonergic and the inflammatory hypotheses of
schizophrenia might be complementary. Aberrant deviation of
tryptophan metabolism to alternative pathways is induced by the
activity of the enzyme indoleamine 2,3-dioxygenase (IDO). Pro-
inflammatory cytokines such as interleukin-2, interferon-γ, and
tumor necrosis factor-α activate IDO, which promotes depletion
of 5-HT and generates a range of metabolites involved in
inflammation, immune response and excitatory
neurotransmission (Hassanain et al., 1993; Stone et al., 2013;
Cervenka et al., 2017). Among the different tryptophan-
dependent metabolites synthesized by IDO, quinolinic acid
(QUIN) and kynurenic acid (KYNA) have been implicated in
the neurobiology of brain disorders (Cervenka et al., 2017). QUIN
is associated with neural excitotoxicity through its N-methyl-D-
aspartate receptor (NMDAR) agonist properties whereas KYNA
exerts neuronal protection due to its ability to antagonize
NMDARs (Stone, 2020). It has been proposed that an aberrant
function of the kynurenine pathway could induce an imbalance
between excitotoxicity/neuroprotection mechanisms that finally
affect FC integrity (Stone et al., 2013). Different studies have
proposed that beyond the acute mechanism of action of atypical
antipsychotic drugs, long-termmechanisms include an important
anti-inflammatory/antioxidant effect, leading to potential
cytoprotective activity (Drzyzga et al., 2006; Sugino et al.,
2009; Ribeiro et al., 2013; de Witte et al., 2014; MacDowell
et al., 2016; MacDowell et al., 2017; Casquero-Veiga et al.,
2019). In this regard, paliperidone administration in mice at
equivalent dose to used in human therapeutics seems to block the
impairments induced byMIA (MacDowell et al., 2017). However,
the long-term consequences on tryptophan metabolic pathways
that could underlay the efficacy of atypical antipsychotic
treatment are, to date, not sufficiently explained.
The aim of the present study was to evaluate whether maternal
viral-like immune activation in early/middle gestation in mice
may induce long-lasting neurochemical changes in the
serotonergic and kynurenine pathways in the FC of adult
offspring. In addition, the effect of long-term atypical
antipsychotic paliperidone treatment on the MIA-induced
alterations was also evaluated.
MATERIAL AND METHODS
Animals and Experimental Model
Pregnant C57BL/6J mice (Envigo, Spain) were injected i.p. with
either 5 mg/kg poly (I:C) (Sigma-Aldrich, United States) or the
vehicle (saline solution) on gestational day 9.5. This period in
mice corresponds to the second third period of pregnancy
(Clancy et al., 2001) and represents a critical moment of brain
development with events that in human gestation occur in the
middle/end of the first trimester (Schepanski et al., 2018). Doses
above 5 mg/kg administered on GD 9.5 have previously shown to
produce physiological, behavioral and neurochemical changes in
the offspring of these mice (Meyer et al., 2008; Holloway et al.,
2013; Prades et al., 2017; MacDowell et al., 2017). Animals were
maintained under standard temperature and humidity conditions
in a 12 h light/dark cycle (lights on at 08:00 h) with free access to
food and water. All experimental protocols were approved by the
Animal Welfare Committee of the University of the Basque
Country and adhered to the guidelines of the European
legislation (European Union Directive 2010/63/UE).
Drug Administration and Experimental
Designs
Male and female pups were born from poly (I:C)-treated and
saline-treated dams and were randomly assigned among four
treatment groups with variables of pre-treatment (poly (I:C) vs.
saline) and drug (paliperidone vs. vehicle). Paliperidone
(PubChem CID:115237; Sigma-Aldrich, Spain) was dissolved
in saline solution with 0.26 mM of acetic acid (vehicle, Veh) to
obtain 0.01 mg/ml, pH adjusted to 7.4. Young-adult animals (≥60
postnatal days; PND) originating from the different litters were
injected i.p. with either paliperidone (0.05 mg/kg, 5 ml/kg) or
vehicle (5 ml/kg) for 21 consecutive days. Group sample sizes (sex
balanced) were poly (I:C)/vehicle, n  9; poly (I:C)/paliperidone,
n  8; saline/vehicle, n  11; saline/paliperidone, n  8. The dose
and duration of paliperidone treatment was selected to be similar
to commonly prescribed human dosages for a 50 kg adolescent
subject, and on the basis of previous in vivo determinations of
behavioral and brain structural abnormalities in poly (I:C)
offspring during adulthood (Piontkewitz et al., 2011; Richtand
et al., 2011; MacDowell et al., 2017). No differences in body
weight between the four animal groups throughout the study
were observed (data not shown).
Preparation of Biological Samples
The animals were subjected to cervical dislocation 48 h after of
the last dose of paliperidone or vehicle treatments. This washout
period is considered adequate to overcome acute effects due to
residual presence of the drug and focus the findings on
modulation exerted by chronic paliperidone administration
(MacDowell et al., 2017). The brain was removed from the
skull and, after careful removal of the meninges and blood
vessels, frontal cortical areas from both brain hemispheres
were excised and frozen at −80°C until assayed.
Western Blot Analysis
Brain FC samples were homogenized by sonication in PBS (pH 
7) mixed with a protease inhibitor cocktail (Complete®, Roche,
Spain). After determining and adjusting protein levels,
homogenates of FC tissue were mixed with Laemmli sample
buffer (Bio-Rad, United States) and β-mercaptoethanol (50 μL/ml
Laemmli), and 15 µg protein were loaded into an electrophoresis
gel. Once separated on the basis of molecular weight, proteins
from the gels were blotted onto a nitrocellulose membrane with a
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semi-dry transfer system (Bio-Rad, United States) and were
incubated with specific antibodies against: 1) tryptophan
hydroxylase 2 (TPH2, 1:1000 in BSA 1%; ab184505, abcam,
United Kingdom); 2) serotonin transporter (SERT, 1:750 in
BSA 2,5%; sc1458, Santa Cruz, United States); 3) serotonin 5-
HT2A receptor (5-HT2AR, 1:1000; sc50397, Santa Cruz,
United States); 4) serotonin 5-HT2C receptor (5-HT2CR, 1:
1000; sc17797, Santa Cruz, United States); 5) monoamine
oxidase A (MAO-A, 1:1000; ab126751, abcam,
United Kingdom); 6) indoleamine 2,3-dioxygenase 1 (IDO1, 1:
750 in BSA 1%; sc25809, Santa Cruz, United States); 7)
indoleamine 2,3-dioxygenase 2 (IDO2, 1:750 in BSA 1%;
NBP2-44174, Novusbio, United Kingdom); 8) kynurenine 3-
monooxygenase (KMO, 1:750 in BSA 1%; NBP2-29936,
Novusbio, United Kingdom); 9) kynurenine aminotransferase
2 (KATII, 1:1000; sc377158, Santa Cruz, United States) and 10)
β-actin (1:10,000; A5441, Sigma-Aldrich, United States). Primary
antibodies were recognized by the respective horseradish
peroxidase-linked secondary antibodies. Blots were imaged
using an Odyssey Fc System (Li-COR, Biosciences, Germany)
and were quantified by densitometry (NIH ImageJ software). In
all the western-blot analyses, the housekeeping β-actin was used
as loading control for normalization. One sample was repeated in
every blot as a variability control to check the possible interassay
unevenness, and each sample was analyzed at least three times in
separate assays. The mean value of each animal were treated as a
single measurement for data analyses. The data are presented as
percentage change respect to the control group.
Kynurenine Pathway Metabolites and
Serotonin Measurement
The levels of tryptophan (BAE-2700, ImmuSmol, United States),
kynurenine (BAE-2200, ImmuSmol, United States), kynurenic
acid (KYNA, CED718Ge, Cloud-Clone, United States),
quinolinic acid (QUIN; CEK552Ge, Cloud-Clone,
United States) and 5-HT (BAE-5900, LDN, Germany) in brain
FC homogenate samples were detected using a commercially
available ELISA-based kit following the manufacturer’s
instructions. The intra- and interassay coefficient of variation
were 11 and 8.4% for tryptophan, 10.3 and 13.3% for kynurenine,
10 and 12% for KYNA and QUIN, 4.1and 9.4% for 5-HT,
respectively.
Quantitative Real-Time Polymerase Chain
Reaction Assays
mRNA expression of serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B,
5-HT2C and 5-HT7 receptors, KAT I, II and III, KMO,
glyceraldehyde-3-phosphate dehydrogenase (GADPH) and
tubulin was evaluated as described in Supplementary information.
Statistical Analyses
The ROUTmethod was performed with a significance Q set at 1%
for the detection of outliers. Two-way ANOVA was used for
comparisons, considering as the first factor the presence or
absence of poly (I:C) and as second factor the presence or
absence of paliperidone treatment. Bonferroni post hoc test
was applied in case of significant interaction (F value p < 0.05)
between factors. All the results of the ANOVA analyses (F values and
dfs) are included in Table 1. A p value ≤0.05 was defined as
statistically significant. The data were analysed using GraphPad
Prism. The data and figures are expressed as mean ± SEM.
RESULTS
Effects of Paliperidone on Serotonin
Neurotransmission After Maternal Immune
Activation
Two-way ANOVA analysis of tryptophan levels in brain FC
samples showed a significant effect for paliperidone treatment
(F(1,29)  6.73, p  0.014) and interaction between factors (F(1,29) 
4.32, p  0.046). Bonferroni post hoc test demonstrated that the
increase in tryptophan levels affected to animals exposed to MIA
treated with paliperidone (Figure 1A).
The conversion from tryptophan to 5-HT depends on the
enzyme TPH2. A significant effect of poly (I:C) exposure (F(1,29) 
8.04, p  0.008) and interaction between main factors (F(1,29) 
6.23, p  0.018) were found. Post hoc analyses showed increased
protein expression of TPH2 in animals exposed to poly (I:C) that
were treated with paliperidone compared to the poly (I:C) group
treated with vehicle (p < 0.05) (Figure 1B). In contrast, post hoc
analyses did not revealed differences between saline and poly (I:
C) groups in absence of paliperidone treatment. In addition,
animals exposed to MIA showed a significant decrease of brain
FC 5-HT levels, and paliperidone treatment induced an
increment of this neurotransmitter in both control and poly
(I:C) conditions (F(1,28)  5.48, p  0.026 and F(1,28)  5.67,
p  0.024, respectively) (Figure 1C).
Other critical elements in the activity of the serotonergic
system were analysed. Two-way ANOVA analysis revealed
that animals exposed to MIA showed a significant increase in
the protein expression of SERT (F(1,29)  18.22, p  0.0002) and 5-
HT2ARs (F(1,29)  6.97, p  0.013) together with a decrease in the
protein expression of 5-HT2CRs (F(1,29)  7.97, p  0.008)
(Figures 1D,F,G). 5-HT2AR/5-HT2CR protein ratio was
increased after MIA insult (Supplementary Figure S1).
However, no differences were found between groups in the
protein expression of MAO-A (Figure 1E). At this point,
paliperidone did not exert any influence on the FC protein
expression of these elements of serotonergic neurotransmission
system. In addition, different 5-HT receptors were also evaluated
at mRNA expression level. The only observed alterations of
mRNA expression were increased 5-HT2ARs linked to poly (I:
C) and decreased 5-HT2CRs induced by paliperidone in poly (I:C)
group (Supplementary Figure S2 and Table S2).
Effects of Paliperidone on Kynurenine
Pathway After Maternal Immune Activation
Tryptophan is also metabolized to kynurenine in the brain by the
enzymes IDO1 and IDO2. Two-way ANOVA analysis of the
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IDO1 protein expression reported a significant effect of
paliperidone treatment and interaction (F(1,29)  12.17, p 
0.001 and F(1,29)  8.32, p  0.007 respectively). Post hoc
analyses showed that paliperidone treatment increased IDO1
protein expression in MIA-exposed (p < 0.001; Figure 2A) but
not in saline-treated animals. In addition, the analysis for IDO2
revealed a significant stimulatory effect of poly (I:C) (F(1,29) 
8.53, p  0.006; Figure 2B). Furthermore, the two-way ANOVA
analysis also indicated a significant decreasing effect of MIA
exposure on kynurenine levels (F(1,29)  5.68, p  0.023;
Figure 2C).
Kynurenine can be transformed into two metabolites with
opposite effects. First, kynurenine is metabolized to QUIN
through multiple-step reactions, that involve KMO enzyme.
Second, kynurenine can be transformed into KYNA mainly by
the KATII enzyme. The mRNA expression of KMO and KAT
isoforms was evaluated. KMO expression increased but not the
different KAT isoforms in response to MIA (Supplementary
Figure S1 and Table S2). When protein expression levels were
analysed, two-way ANOVA analysis of KMO found a significant
effect of MIA, paliperidone treatment and interaction (F(1,29) 
5.28, p  0.003; F(1,29)  10.99, p  0.002; and F(1,29)  8.41, p 
0.007, respectively). Post hoc analyses reported that MIA
increased KMO expression (p < 0.01) and that paliperidone
treatment decreased KMO protein expression in MIA
conditions (p < 0.001) (Figure 2D). In contrast, no significant
change was found in the KATII protein expression analyses
(Figure 2E). Regarding the kynurenine metabolites, a trend to
increase of QUIN levels by MIA exposure was observed, although
it did not reach statistical significance (F(1,29)  3.37; p  0.076)
(Figure 2F). However, for KYNA levels, no alterations were
observed (Figure 2G).
Finally, the ratio between QUIN and KYNA levels was
calculated as a possible indicator of cytotoxicity risk. Two-way
ANOVA analysis indicated a significant effect of interaction
between the factors (F(1,29)  6.99; p  0.013). Post hoc
analyses reported that MIA animals showed an increased
cytotoxic ratio compared to saline group in absence of
treatment (p < 0.05) and that long-term paliperidone is able to
reverse such increase in poly (I:C) MIA animals (p < 0.05)
(Figure 2H).
DISCUSSION
The present study shows that a single maternal exposure to the
immunoreactive agent poly (I:C) in early/middle brain
development during pregnancy in mice is sufficient to induce
long-lasting changes of the 5-HT neurotransmission system in
the FC of adult offspring. This fact seems to match with the
activation of alternative metabolic pathways of L-tryptophan,
probably induced by the presence of pro-inflammatory
conditions in the brain of affected mice (Song et al., 2011; Volk
et al., 2015; MacDowell et al., 2017). Indeed, an imbalance between
metabolic products of the kynurenine pathway emerges shifting
towards a pro-cytotoxic status. Previous studies performed in the
MIA animal model generated in the same mice strain (C57BL/6), at
the same dose and route of administration of poly (I:C) (5 mg/kg i.p.)
and at the same gestational day (9.5) have shown behavioral
abnormalities (MacDowell et al., 2017; Prades et al., 2017). These
facts support the idea thatMIA-induced impacts in serotonergic and
kynurenine pathways may contribute to the behavioral impairments
in the model. On the other hand, chronic paliperidone treatment
counterbalances the impairments induced byMIA insult and thus, it
could partially explain the ability of atypical antipsychotics to
ameliorate some of the schizophrenia-related behavioral
impairments previously observed in this specific animal model of
the disorder (Meyer et al., 2010; Piontkewitz et al., 2011; Richtand
et al., 2011; Dickerson and Bilkey, 2013; MacDowell et al., 2017).
Effects of Paliperidone on Serotonin
Neurotransmission After Maternal Immune
Activation
In mice subjected to MIA, a decrease on tissue 5-HT content was
observed. The finding agrees with the observation that
TABLE 1 | Two-way ANOVA analyses (F, df and p values) of protein expression and metabolites determination. Bold: statistically significant values. WB, western blot
experiments.
Parameter Poly (I:C) Treatment Interaction
Tryptophan F(1,29)  0.03; p  0.872 F(1,29) = 6.73; p = 0.014 F(1,29)= 4.32; p = 0.046
WB TPH2 F(1,29) = 8.04; p = 0.008 F(1,29)  2.33; p  0.137 F(1,29) = 6.23; p = 0.018
5-HT F(1,28) = 5.48; p = 0.026 F(1,28) = 5.67; p = 0.024 F(1,28)  0.08; p  0.773
WB SERT F(1,29) = 18.22; p < 0.001 F(1,29)  2.52; p  0.123 F(1,29)  0.72; p  0.404
WB MAO-A F(1,29)  0.18; p  0.671 F(1,29)  0.31; p  0.581 F(1,29)  0.02; p  0.902
WB 5-HT2AR F(1,29) = 6.97; p = 0.013 F(1, 29)  0.13; p  0.721 F (1, 29)  0.03; p  0.872
WB 5-HT2CR F(1,29) = 7.97; p = 0.008 F(1,29)  0.25; p  0.623 F(1,29)  0.02; p  0.895
WB IDO1 F(1,29)  0.00; p  0.984 F(1,29) = 12.17; p = 0.001 F(1,29) = 8.32; p = 0.007
WB IDO2 F(1,29) = 8.53; p = 0.006 F(1,29)  1.45; p  0.238 F(1,29)  0.52; p  0.477
Kynurenine F(1,29) = 5.68; p = 0.023 F(1,29)  0.22; p  0.645 F(1,29)  0.01; p  0.907
WB KMO F(1,29) = 5.28; p = 0.003 F(1,29) = 10.99; p = 0.002 F(1,29) = 8.41; p = 0.007
QUIN F(1,29)  3.37; p  0.076 F(1,29)  0.34; p  0.566 F(1,29)  0.27; p  0.606
WB KATII F(1,29)  2.73; p  0.109 F(1,29)  0.14; p  0.706 F(1,29)  0.02; p  0.880
KYNA F(1,29)  1.34; p  0.256 F(1,29)  0.32; p  0.574 F(1,29)  0.08; p  0.772
QUIN/KYNA ratio F(1,29)  2.85; p  0.102 F(1,29)  3.61; p  0.067 F(1,29) = 6.99; p = 0.013
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FIGURE 1 | Effects of paliperidone on 5-HT neurochemical processes after MIA in mice FC. Tryptophan levels (A), protein expression of TPH2 (B), 5-HT levels (C)
and protein expression of SERT, MAO-A, 5-HT2A and 5-HT2C receptors (D–G) in the FC of mice treated with vehicle (Veh) or paliperidone (Pali) in control (Saline) and
prenatal poly (I:C) administration. The densitometric data of the respective immunoreactive bands were normalized by β-actin. In the (B,F,G) panels, blots were cropped
(black lines) for improving the clarity and conciseness of the presentation. Bars represent means ± SEM. The number of experiments in all parameters analyzed was
between 8-9 animals. Two-way ANOVA: &p <0.05, &&p < 0.01, &&&p < 0.001 for poly(I:C) factor; #p < 0.05 for treatment factor. *p < 0.05 vs poly (I:C)+Veh group
(Bonferroni post hoc test after significant interaction).
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FIGURE 2 | Effects of paliperidone on kynurenine metabolic pathways after MIA in mice FC. Protein expression of IDO1 and IDO2 (A,B), kynurenine levels (C),
protein expression of KMO and KATII (D,E), QUIN levels (F), KYNA levels (G) and cytotoxicity risk ratio (H) in the FC of mice treated with vehicle (Veh) or paliperidone (Pali)
in control (Saline) and prenatal poly (I:C) administration. The densitometric data of the respective immunoreactive bands were normalized by β-actin. In the (A,B,D)
panels, blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Bars represent means ± SEM. The number of experiments in
all parameters analyzed was between 8-9 animals.Two-way ANOVA: &p <0.05 and &&p <0.01 for poly(I:C) factor. #p <0.05, ##p <0.01 vs saline+Veh group; *p < 0.05,
***p < 0.001 vs poly (I:C)+Veh group (Bonferroni post hoc test after significant interaction).
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intracerebroventricular injection of the cytokines that are released
in response to poly (I:C) (Meyer et al., 2006; Cunningham et al.,
2007) decreases 5-HT concentrations in the FC (Kamata et al.,
2000). Likewise, a decrease in the rat brain cortical 5-HT content
was observed in the offspring born from bacterial toxin
lipopolysaccharide-immune-challenged mothers (Swanepoel
et al., 2018). However, there are also studies reporting
unaltered tissue 5-HT concentrations in the FC of MIA
animal models (Winter et al., 2009; Abazyan et al., 2010;
Hadar et al., 2015; Goh et al., 2020). The discrepancies
highlight the importance of the intensity of MIA, as evidenced
by the dose of immunogenic substance used, as well as the impact
on the neurodevelopmental trajectory in relation to gestation
time for the MIA. The 5-HT decrease was reversed by
paliperidone treatment, demonstrating that antipsychotic drugs
can ameliorate the consequences of prenatal MIA insult on
neurotransmitter concentrations. In agreement with the results
presented here, a role for 5-HT alterations in the pathophysiology
of schizophrenia has been repeatedly postulated. It has been
proposed that 5-HT dysregulation in schizophrenia patients
could be the cause of the negative symptoms and high rates of
comorbid depression observed in the disorder (Abi-Dargham,
2007; Selvaraj et al., 2014). In that sense, reduction of brain 5-HT
synthesis exerted by acute tryptophan depletion (Carpenter et al.,
1998), has been shown to worsen negative symptoms (Sharma
et al., 1997). In addition, selective serotonin reuptake inhibitors
have been proven to be effective in treatment of the negative
symptoms of the disease (Singh et al., 2010). Monoamine tissue
concentrations are mainly the end result of synthesis from amino
acid precursors and reuptake mechanism from the extracellular
space. In the present study, tissue levels of the 5-HT precursor
L-tryptophan and the TPH2, considered the limiting synthesis
enzyme, were not significantly altered by MIA under basal
conditions. Interestingly, paliperidone treatment increased the
availability of the precursor L-tryptophan and TPH2 protein
expression in poly (I:C) mice but not in controls, suggesting
that long-term antipsychotic treatment could trigger
compensatory mechanisms that contribute to restoration of
the tissular content of 5-HT in the MIA model. However,
tissue 5-HT content is also sensitive to paliperidone in control
animals, which indicates the existence of other complementary
mechanisms of paliperidone to increase tissue 5-HT content. The
results seem to indicate that deficits of 5-HT in the cortex of poly
(I:C) mice are not related to neurotransmitter synthesis
alterations and point to a potential deviation of tryptophan
metabolism towards alternative pathways, probably induced by
the existence of a proinflammatory status in the FC. Regarding
the other critical step in steady-state tissue 5-HT content, an
increased expression of the selective reuptake protein SERT was
observed in poly (I:C) MIA mice. Since this SERT overexpression
did not overcome 5-HT depletion, it could be interpreted as a
compensatory mechanism to restore adequate neurotransmitter
levels more than a direct effect of MIA activation. In fact, no
changes in SERT levels in frontal (Malkova et al., 2014),
orbitofrontal and prelimbic cortex (Goh et al., 2020) have
been seen in other studies of MIA poly (I:C) rodents. In
contrast, another study revealed an increase of hippocampal
SERT protein in poly (I:C) animals (20 mg/kg on gestational
day 12.5) (Reisinger et al., 2016) suggesting extensive adaptation
after MIA in different brain areas. In the present study, the
influence of MIA on SERT was less apparent after paliperidone
treatment, a condition in which 5-HT was higher, supporting to
the hypothesis that SERT modulation represents a compensatory
mechanism to overcome tissue 5-HT deficits. On the contrary,
MAO-A, the catabolic enzyme that metabolizes different
monoamines, including 5-HT, was not altered by either MIA
or paliperidone treatment, ruling out the contribution of 5-HT
metabolism to neurobiological alterations induced by the present
MIA model.
In order to evaluate the MIA-induced alterations on 5-
HT2ARs and 5-HT2CRs in the offspring, both the mRNA and
the protein expression were evaluated. 5-HT2AR mRNA
expression showed an increase in poly (I:C) mice that was
associated to changes in protein expression. Similar findings
have been previously reported in mice (Malkova et al., 2014) and
rat offspring exposed prenatally to another immunoactive
trigger (lipopolysaccharide on gestational days 15 and 16)
(Wischhof et al., 2015). Radioligand binding assays also
showed enhanced 5-HT2AR density in FC membranes of
mice born from poly (I:C) and influenza-injected mothers
(Moreno et al., 2011; Holloway et al., 2013). Moreover, it has
been demonstrated that poly (I:C) offprings do not show basal
hallucinogenic-like alterations but display supersensitivity of
the head-twich response, a proxy of hallucinogenic behavior, to
the administration of 5-HT2AR agonists such as 2,5-dimethoxy-
4-iodoamphetamine (DOI) and LSD (Gonzalez-Maeso et al.,
2007; Holloway et al., 2013; Malkova et al., 2014; Wischhof et al.,
2015). This finding is compatible with a supersensitivity of 5-
HT2ARs. In the present study, MIA mice also showed reduced
protein (but not mRNA) expression of 5HT2CRs. This decrease
could be a consequence of compensatory mechanisms induced
by the 5-HT2AR dysfunction. Several lines of evidence
demonstrated that 5-HT2ARs and 5-HT2CRs oppositely affect
neurochemical release within the FC (Alex and Pehek, 2007) as
well as inversely control of certain behaviors (Bubar and
Cunningham, 2006). According to this, the present results
also suggest the existence of a misbalance between 5-HT2R
subtypes after MIA insult that could also contribute to
alterations of serotonergic neurotransmission system.
Paliperidone when administered at active therapeutic dose
did not evoke any noteworthy effects on 5-HT2AR and 5-
HT2CR protein expression in control and MIA animals. This
seems to indicate that paliperidone reversion of impairments
induced on the 5-HT system (present results) and behavior
(MacDowell et al., 2017) by MIA are not the consequence of a
direct modulation of the receptor expression by this
antipsychotic drug. On the other hand, the relationships
between MIA and the expression of the different 5-HT
receptors is unknown. For this reason, complementary
mRNA expression of 5-HT1A, 5-HT1B, 5-HT2B and 5-HT7
receptors was performed. No differences were observed in
the mRNA expression levels of these receptors neither in
MIA mice nor in treated animals confirming that MIA seems
to exert a selective alteration on 5-HT2Rs.
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Effects of Paliperidone on Kynurenine
Pathway After Maternal Immune Activation
Kynurenine synthesis is one of the best-known alternative
pathways of tryptophan metabolism. Tryptophan is deviated
from 5-HT synthesis process to kynurenine pathway in
response to inflammatory mediators acting on IDO enzymes.
The kynurenine pathway yields different metabolites with
neurotoxic and neuroprotective properties, the predominant
action being dependent upon enzymes expression and cell-
type activity (Stone and Darlington, 2002; Haroon et al., 2012;
Cervenka et al., 2017). KYNA is a kynurenine metabolite
synthesized mainly by KAT enzymes in astrocytes and that
shows antagonist properties on NMDARs and α7-cholinergic
nicotinic receptors. Another kynurenine metabolic product is
QUIN, an agonist of the NMDARs (Stone and Darlington, 2002)
that is mainly synthetized in microglia by KMO enzyme. Several
lines of evidence indicate the existence of alterations in the main
enzymes and metabolites of the kynurenine pathway after different
MIA protocols (Khalil et al., 2013; Zavitsanou et al., 2014; Clark et al.,
2019). These studies showed in rats that modulation is greatly
influenced by the immunoactive dose, the gestational day of
administration, and more importantly, by the postnatal age
chosen for evaluation of the alterations (Clark et al., 2019).
Accordingly, the present results showed a dysregulation of
kynurenine pathway in adult mice littermates of poly (I:C)
immuno-challenged mothers. Immunoblotting assays of IDO
enzymes revealed that MIA offspring have increased protein
expression of IDO2 but not IDO1 and that paliperidone
treatment triggered a striking stimulatory effect on IDO1 protein
expression, but did not influence IDO2. IDO1 represents a highly
efficient for tryptophan metabolism under physiological conditions
that is inducible by several pro-inflamatory factors and stress. In
contrast, IDO2 physiological involvement is less known but
transcripts are expressed in brain microglia (Brooks et al., 2017)
and the enzyme seems to play a role under autoinmune
inflammatory conditions (Larkin et al., 2016; Jusof et al., 2017).
In the same line of evidence, KMO expression was increased by
MIA and reversed after paliperidone treatment, whereas KATII
remained unaffected. Probably, as consequence of these
dysregulations, the intermediate metabolite kynurenine
decreased in MIA mice. The finding suggests the existence of
microglia activation as cellular substratum of KMO
overexpression whereas astrocytes, the principal source of
KATII, remain unaltered in response to prenatal
administration of poly (I:C). More interestingly, QUIN but
not KYNA, the end active products, seems to be increased in
MIA mice, pointing to a selective hyperactivation of the
cytotoxic arm of kynurenine pathway. KMO enzyme, similar
to IDO, is induced by inflammatory mediators in several cell
types whereas KAT isoforms are unimpacted (Fujigaki et al.,
2017).
A fine-tuning of KYNA and QUIN levels seems to be a
relevant factor in establishing a correct balance between the
protective and deleterious effects induced respectively by these
compounds through interaction with NMDARs. In the present
study, the QUIN/KYNA ratio calculated as a cytotoxicity risk
index increased in MIA groups and was reduced by long-term
paliperidone treatment in the group of animals with prenatal
MIA. These findings stress the importance of measuring the ratio
of the different kynurenines more than particular metabolites as
complementary indicators of kynurenine pathway imbalances in
animal and human studies of neuropsychiatric disorders. In
addition, it has been observed a decrease in the serum
kynurenic acid concentration and an increase of quinolinic
acid in rat littermates of poly (I:C) immuno-challenged
mothers. This fact suggests that other tissues different than
brain could be also affected by increased cytotoxicity risk
index in MIA animals (Zavitsanou et al., 2014).
CONCLUSION
The present study was prompted by previous findings
demonstrating that the administration of paliperidone to
offspring of poly (I:C)-treated dams prevented the emergence
of proinflammatory and behavioral abnormalities in adulthood
(MacDowell et al., 2017). According with the present results, the
impairment of serotonergic function may be part of complex
neuropathological processes induced by aberrant immunological
activation of kynurenine pathways that contribute to a cytotoxic
imbalance in the FC of poly (I:C) offspring mice, and that chronic
treatment with paliperidone during adulthood may, at least in
part, prevent such neuropathological processes. Further studies
on the effects of infectious agents on neurodevelopment are
required, particularly in view of recent outbreaks of infectious
diseases (such as H1N1 influenza, Zika virus or more recently,
SARS-CoV-2) suggesting that offspring of infected pregnant
women might be high-risk groups for severe and long-lasting
complications of psychiatric diseases.
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